Home > Result Summaries: Compounds > Hepatitis B Vaccine, Adjuvanted Result Summaries: Hepatitis B Vaccine, Adjuvanted GSKStudy ID Phase Title Summary (Download) 105757 phase 3 Study comparing the immunogenicity and safety of an investigational vaccination regimen to that of GSK Bio’s adjuvanted hepatitis B vaccine, Fendrix®, administered according to 0, 1, 2, 6 months schedule, in hepatitis B naïve pre-dialysis, peritoneal dialysis and haemodialysis patients (≥ 15 years o (1 citation(s)) 105758 phase 3 Long-term follow-up study to evaluate the persistence of anti-HBs antibodies at Months 12, 24 and 36 in pre-dialysis / peritoneal dialysis or haemodialysis patients who had previously received a primary vaccination course of either an investigational vaccination regimen or GSK Biologicals' FendrixTM (1 citation(s))
